Stockscreener 앱 받기
92.95
0.77%
0.71
시간 외 거래:
93.39
0.44
+0.47%
Incyte Corp 주식(INCY)의 최신 뉴스
Incyte (NASDAQ: INCY) R&D head exercises options, sells 18,667 shares - Stock Titan
Incyte Corp Stock (ISIN: US45337C1027) Faces Pressure Amid Oncology Pipeline Setbacks and Market Vol - AD HOC NEWS
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Incyte Corp. (INCY) reports Q4 2025 revenue growth of 28% to $1.51B driven by Jakafi and Opzelura sales - MSN
Faithward Advisors LLC Takes $4.45 Million Position in Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Strengthens Partnership with Knight for MINJUVI in Latin America - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Form 144: INCY (NASDAQ: INCY) reports 18,667-share stock option sale - Stock Titan
INCY's phase III Monjuvi study meets key goals in first-line lymphoma - MSN
Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue (NASDAQ:INCY) - Seeking Alpha
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
INCY wins EC approval for label expansion of oncology drug Zynyz - MSN
How Diverging Zynyz Outcomes In Cancer Trials At Incyte (INCY) Have Changed Its Investment Story - simplywall.st
Incyte (INCY) Downgraded by Jefferies; Price Target Lowered | IN - GuruFocus
Jefferies downgrades Incyte stock rating on patent cliff concerns - Investing.com
Incyte Drug Zynyz Approved in Europe for Anal Canal Cancer Treatment - MyChesCo
How Investors Are Reacting To Incyte (INCY) Winning EU Approval For Zynyz In Advanced Anal Cancer - Yahoo Finance
Incyte Corporation (NASDAQ:INCY) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
INCYIncyte Corp Stock Price and Quote - Finviz
European Commission Approves J&J Prostate Drug, PLX Fabry Dosing, Incyte's Zynyz Second Indication - RTTNews
Mackenzie Financial Corp Has $38.43 Million Stock Holdings in Incyte Corporation $INCY - MarketBeat
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte (INCY) Down 4.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention - MSN
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Incyte Advances New Early Stage Drug INCA033989 Into Human Testing - TipRanks
Incyte at Barclays Conference: Navigating Post-Jakafi Future - Investing.com
Russell Investments Group Ltd. Has $68.44 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Korea Investment CORP Raises Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com
Incyte Corporation $INCY Shares Purchased by Vestcor Inc - MarketBeat
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Finviz
Incyte becomes third company to receive CRL over issues at Novo Indiana factory - Endpoints News
Stifel reiterates Incyte stock rating after FDA setback - Investing.com
Incyte (NASDAQ:INCY) Receives Buy Rating from HC Wainwright - MarketBeat
WINTON GROUP Ltd Acquires 213,557 Shares of Incyte Corporation $INCY - MarketBeat
A Glimpse Into The Expert Outlook On Incyte Through 13 Analysts - Benzinga
INCY: Today's Analyst Rating Update by HC Wainwright & Co. | INC - GuruFocus
Incyte wins EC approval of Zynyz for SCAC - The Pharmaletter
Meiji Yasuda Asset Management Co Ltd. Has $2.34 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - BioSpace
Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp - MSN
Incyte Corporation $INCY Stake Reduced by Vinva Investment Management Ltd - MarketBeat
Assessing Incyte (INCY) Valuation After EC Approval Of Zynyz For Advanced Anal Cancer - simplywall.st
FDA Declines New Indication for Incyte's (INCY) Zynyz Due to Man - GuruFocus
Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant - Seeking Alpha
Incyte (INCY) Gains EC Approval for Combination Therapy with Zyn - GuruFocus
Incyte Corporation (INCY) Receives FDA Complete Response Letter for Zynyz® sBLA - GuruFocus
FDA issues complete response letter for Incyte’s Zynyz application in lung cancer - Investing.com
Assessing Incyte (INCY) Valuation After Recent Share Price Weakness And Mixed Fair Value Signals - Yahoo Finance
FDA issues CRL for Incyte sBLA for Zynyz in NSCLC over third-party facility inspection - TradingView
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
New first-line treatment for advanced anal cancer gets EU approval - Stock Titan
Incyte Momentum Builds With Strong Cash Flows Ahead Of Key Conference - Yahoo Finance
Incyte Corp. stock outperforms competitors despite losses on the day - MSN
(retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - Business Wire
Today's Analyst Rating Update on Incyte (INCY): Evercore ISI Gro - GuruFocus
Incyte Corporation $INCY Shares Bought by Victory Capital Management Inc. - MarketBeat
INCY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Teachers Retirement System of The State of Kentucky Has $30.18 Million Stake in Incyte Corporation $INCY - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):